Bone Biologics Co. (NASDAQ:BBLGW) Short Interest Up 44.4% in April

Bone Biologics Co. (NASDAQ:BBLGW) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 1,300 shares, a growth of 44.4% from the March 31st total of 900 shares. Based on an average daily trading volume, of 1,800 shares, the short-interest ratio is presently 0.7 days.

Bone Biologics Price Performance

NASDAQ:BBLGW traded down $1.04 on Friday, hitting $22.00. The company’s stock had a trading volume of 1,654 shares, compared to its average volume of 2,960. The stock has a fifty day moving average of $15.46 and a two-hundred day moving average of $8.44. Bone Biologics has a one year low of $0.43 and a one year high of $44.15.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.